Metal-organic frameworks and peripheral immune tolerance were the big winners of the Nobel prizes in chemistry, and in physiology or medicine, respectively. In this episode of the podcast, we discuss the winners and the impacts of their discoveries. Then we move over to some business news where we discuss a novel gene therapy for Huntington’s disease from uniQure that made waves recently. Early clinical trial data for AMT-130 showed that it could meaningfully slow the progression of the disease by as much as 75%. Also in business news, a new partnership involving Arbor Biotechnologies and Chiesi Group aims to develop gene editing therapies to target rare liver diseases.
Listed below are links to the GEN stories referenced in this episode of Touching Base.
Uduak Thomas, GEN, October 6, 2025
Metal-Organic Frameworks Win the 2025 Nobel Prize in Chemistry
Julianna LeMieux, PhD, GEN, October 8, 2025
Gene Therapy Significantly Slows Huntington Disease Progression
GEN, September 24, 2025
StockWatch: uniQure Shares Reach Five-Year High on “Game Changing” Huntington’s Data
Alex Philippidis, GEN Edge, September 28, 2025
Chiesi, Arbor Target Rare Liver Diseases in Up-to-$2.1B Gene Editing Collaboration
Alex Philippidis, GEN Edge, October 8, 2025
Hosted by Corinna Singleman, PhD
Hosted by Jonathan D. Grinstein, PhD
